PURPOSE: We evaluated the distribution and clinical impact of @entity470 , @entity984 and @entity1722 copy number gains and @entity470 , @entity984 and @entity817 activating mutations in resected @entity1149 ( @entity1149 ) from 151 Polish @entity1 . MATERIALS AND METHODS: Quantitative PCR and DNA sequencing were used for copy number evaluation and mutational analysis, respectively. RESULTS: An increased @entity470 CN was found in 21.2% of the @entity5 , more commonly of the non-squamous histology (P=0.029), larger in size (P=0.004) and those obtained from @entity1 (P=0.040). @entity1722 copy gain was observed in 21.8% of the @entity1 , more frequently with lymph node @entity3 (P=0.048) and stage IIIA disease (P=0.061). @entity984 gain was found in 29.3% of the @entity5 , and was not associated with @entity1 ' clinicopathological features. No @entity817 mutations were found. @entity470 and @entity984 mutation frequency and associations with clinicopathological characteristics did not differ significantly from those previously described for the NSCLC @entity1 of Caucasian ethnicity. Strong associations existed between most of the analyzed alterations. In the multivariate model, @entity470 mutations constituted an independent prognostic factor of the disease recurrence in @entity420 @entity1 (HR 7.20; 95%CI 1.31-39.48; P=0.023), while an increased @entity470 copy number tended to indicate a shorter overall survival (HR 4.85; 95%CI 0.92-25.58; P=0.062). CONCLUSIONS: @entity470 pathway genes alterations are frequent in @entity1149 from Polish @entity1 and have a prognostic potential for @entity1 ' clinical outcome after a curative @entity5 resection. Gene CN evaluation by quantitative PCR provides comparable results and enables assay standardization, yet the optimal scoring system needs to be developed.

Significance of @entity470 signaling pathway genetic alterations in radically resected XXXX from a Polish cohort. One institutional study.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLCs', 'non-small cell lung cancers'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity817 :: ('673', 'Gene') :: ['BRAF'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancers']
